Literature DB >> 15564813

Aripiprazole and atypical neuroleptic malignant syndrome.

Scott Spalding, Norman E Alessi, Karam Radwan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564813     DOI: 10.1097/01.chi.0000142277.95052.94

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


× No keyword cloud information.
  8 in total

1.  Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report.

Authors:  Daniel Molina; Leslie E Tingle; Xiaohui Lu
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia.

Authors:  Laura S Boylan; Scott Hirsch
Journal:  BMJ Case Rep       Date:  2009-02-02

Review 3.  Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review.

Authors:  Rachel Neuhut; Jean-Pierre Lindenmayer; Raul Silva
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-08       Impact factor: 2.576

Review 4.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Atypical neuroleptic malignant syndrome.

Authors:  Ann Collins; Drew Davies; Sharmila Menon
Journal:  BMJ Case Rep       Date:  2016-06-13

6.  Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge.

Authors:  David Choon Liang Teo; Hon Khuan Wong; Sheng Neng Tan
Journal:  Innov Clin Neurosci       Date:  2018-08-01

7.  A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder.

Authors:  Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

Review 8.  Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective.

Authors:  Lurdes Tse; Alasdair M Barr; Vanessa Scarapicchia; Fidel Vila-Rodriguez
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.